ArticleThe oncologist2018

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Patrizia Mondello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.